Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago. Results of the initial dose escalation study in patients with metastatic cancer showed that ISIS-STAT3Rx treatment resulted in partial responses that were durable and prolonged in two out of three patients with diffuse large B-cell lymphoma (DLBCL) who were refractory to prior chemotherapy treatments. Isis and AstraZeneca are currently evaluating ISIS-STAT3Rx, in two clinical studies in patients with advanced lymphoma and metastatic liver cancer.
Read more here:
http://www.heraldonline.com/2013/06/03/4913337/isis-pharmaceuticals-reports-encouraging.html
by WORLD DRUG TRACKER
DR ANTHONY CRASTO
Sorry, the comment form is closed at this time.